Filing Flows › Beam Therapeutics (BEAM) › Q3 2025
Beam Therapeutics (BEAM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Beam Therapeutics (BEAM) reported revenue of $9.7M for the third quarter 2025 (Q3 2025), -32% from a year earlier and +15% from the quarter before.
Beam Therapeutics, Q3 2025: revenue $9.7M (-32% year over year), net loss $113M, operating cash flow −$81.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.7M | +15% | -32% |
| Operating profit | −$127M | — | — |
| Net earnings | −$113M | — | — |
| Operating cash flow | −$81.5M | — | — |
What changed
Revenue was $9.7M in Q3 2025, down 32% year over year and up 15% from the previous quarter.
Operating costs exceeded revenue by $126.8M, an operating margin of -1307.6%. Total costs grew 13% against a revenue fall of 32%. The fastest-growing cost line was Research & development (+16%). The quarter ended with a net loss of $112.6M, wider than the previous quarter's $102.1M loss.
Operating cash flow was −$81.5M. Non-cash charges added back $5.6M of depreciation and $22.7M of share-based compensation. Capital expenditures of $5.0M exceeded it, leaving free cash flow of −$86.5M.
Questions
What was Beam Therapeutics' revenue in the third quarter 2025?
Beam Therapeutics (BEAM) reported revenue of $9.7M for the third quarter 2025 (Q3 2025), -32% from a year earlier and +15% from the quarter before.
Source: Beam Therapeutics 10-Q on SEC EDGAR.